vs
ASGN Inc（ASGN）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是ASGN Inc的1.5倍（$1.4B vs $970.0M），瑞思迈净利率更高（27.6% vs 0.6%，领先27.0%），瑞思迈同比增速更快（11.0% vs -3.0%），瑞思迈自由现金流更多（$311.2M vs $9.1M），过去两年瑞思迈的营收复合增速更高（9.0% vs -3.2%）
ASGN Inc是总部位于美国的领先专业服务与人力资源解决方案供应商，主营信息技术、创意设计、生命科学、工程等领域的技术人才供给及咨询服务，主要服务北美地区的企业级客户。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
ASGN vs RMD — 直观对比
营收规模更大
RMD
是对方的1.5倍
$970.0M
营收增速更快
RMD
高出14.0%
-3.0%
净利率更高
RMD
高出27.0%
0.6%
自由现金流更多
RMD
多$302.1M
$9.1M
两年增速更快
RMD
近两年复合增速
-3.2%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $970.0M | $1.4B |
| 净利润 | $5.5M | $392.6M |
| 毛利率 | 27.5% | 61.8% |
| 营业利润率 | 2.9% | 34.6% |
| 净利率 | 0.6% | 27.6% |
| 营收同比 | -3.0% | 11.0% |
| 净利润同比 | -73.7% | 13.9% |
| 每股收益（稀释后） | $0.13 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASGNRMD
| Q1 26 | $970.0M | — | ||
| Q4 25 | $980.1M | $1.4B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $968.3M | $1.3B | ||
| Q4 24 | $985.0M | $1.3B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.0B | $1.2B |
净利润ASGNRMD
| Q1 26 | $5.5M | — | ||
| Q4 25 | $25.2M | $392.6M | ||
| Q3 25 | $38.1M | $348.5M | ||
| Q2 25 | $29.3M | $379.7M | ||
| Q1 25 | $20.9M | $365.0M | ||
| Q4 24 | $42.4M | $344.6M | ||
| Q3 24 | $47.5M | $311.4M | ||
| Q2 24 | $47.2M | $292.2M |
毛利率ASGNRMD
| Q1 26 | 27.5% | — | ||
| Q4 25 | 28.9% | 61.8% | ||
| Q3 25 | 29.4% | 61.5% | ||
| Q2 25 | 28.7% | 60.8% | ||
| Q1 25 | 28.4% | 59.3% | ||
| Q4 24 | 29.0% | 58.6% | ||
| Q3 24 | 29.1% | 58.6% | ||
| Q2 24 | 29.1% | 58.5% |
营业利润率ASGNRMD
| Q1 26 | 2.9% | — | ||
| Q4 25 | 5.7% | 34.6% | ||
| Q3 25 | 6.7% | 33.4% | ||
| Q2 25 | 5.8% | 33.7% | ||
| Q1 25 | 4.8% | 33.0% | ||
| Q4 24 | 7.5% | 32.5% | ||
| Q3 24 | 7.7% | 31.6% | ||
| Q2 24 | 7.8% | 31.2% |
净利率ASGNRMD
| Q1 26 | 0.6% | — | ||
| Q4 25 | 2.6% | 27.6% | ||
| Q3 25 | 3.8% | 26.1% | ||
| Q2 25 | 2.9% | 28.2% | ||
| Q1 25 | 2.2% | 28.3% | ||
| Q4 24 | 4.3% | 26.9% | ||
| Q3 24 | 4.6% | 25.4% | ||
| Q2 24 | 4.6% | 23.9% |
每股收益（稀释后）ASGNRMD
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.58 | $2.68 | ||
| Q3 25 | $0.87 | $2.37 | ||
| Q2 25 | $0.67 | $2.58 | ||
| Q1 25 | $0.48 | $2.48 | ||
| Q4 24 | $0.94 | $2.34 | ||
| Q3 24 | $1.06 | $2.11 | ||
| Q2 24 | $1.02 | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $143.6M | $1.4B |
| 总债务越低越好 | $1.5B | $403.9M |
| 股东权益账面价值 | $1.8B | $6.3B |
| 总资产 | $4.0B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.82× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ASGNRMD
| Q1 26 | $143.6M | — | ||
| Q4 25 | $161.2M | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $932.7M | ||
| Q4 24 | $205.2M | $521.9M | ||
| Q3 24 | — | $426.4M | ||
| Q2 24 | — | $238.4M |
总债务ASGNRMD
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | $403.9M | ||
| Q3 25 | $1.2B | $408.7M | ||
| Q2 25 | $1.2B | $658.4M | ||
| Q1 25 | $1.3B | $663.1M | ||
| Q4 24 | $1.0B | $662.9M | ||
| Q3 24 | $1.0B | $667.6M | ||
| Q2 24 | $1.0B | $697.3M |
股东权益ASGNRMD
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $6.3B | ||
| Q3 25 | $1.8B | $6.1B | ||
| Q2 25 | $1.8B | $6.0B | ||
| Q1 25 | $1.8B | $5.5B | ||
| Q4 24 | $1.8B | $5.3B | ||
| Q3 24 | $1.8B | $5.2B | ||
| Q2 24 | $1.8B | $4.9B |
总资产ASGNRMD
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $8.5B | ||
| Q3 25 | $3.7B | $8.3B | ||
| Q2 25 | $3.7B | $8.2B | ||
| Q1 25 | $3.7B | $7.6B | ||
| Q4 24 | $3.4B | $7.1B | ||
| Q3 24 | $3.4B | $7.2B | ||
| Q2 24 | $3.5B | $6.9B |
负债/权益比ASGNRMD
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.65× | 0.06× | ||
| Q3 25 | 0.64× | 0.07× | ||
| Q2 25 | 0.66× | 0.11× | ||
| Q1 25 | 0.72× | 0.12× | ||
| Q4 24 | 0.58× | 0.13× | ||
| Q3 24 | 0.58× | 0.13× | ||
| Q2 24 | 0.57× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $9.1M | $311.2M |
| 自由现金流率自由现金流/营收 | 0.9% | 21.9% |
| 资本支出强度资本支出/营收 | 1.0% | 2.0% |
| 现金转化率经营现金流/净利润 | — | 0.87× |
| 过去12个月自由现金流最近4个季度 | $290.6M | $1.8B |
8季度趋势，按日历期对齐
经营现金流ASGNRMD
| Q1 26 | — | — | ||
| Q4 25 | $102.3M | $339.7M | ||
| Q3 25 | $83.9M | $457.3M | ||
| Q2 25 | $124.9M | $538.8M | ||
| Q1 25 | $16.8M | $578.7M | ||
| Q4 24 | $100.2M | $308.6M | ||
| Q3 24 | $135.8M | $325.5M | ||
| Q2 24 | $90.7M | $440.1M |
自由现金流ASGNRMD
| Q1 26 | $9.1M | — | ||
| Q4 25 | $93.7M | $311.2M | ||
| Q3 25 | $72.0M | $414.4M | ||
| Q2 25 | $115.8M | $508.2M | ||
| Q1 25 | $6.6M | $557.9M | ||
| Q4 24 | $88.9M | $288.0M | ||
| Q3 24 | $127.9M | $307.7M | ||
| Q2 24 | $85.4M | $415.2M |
自由现金流率ASGNRMD
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.6% | 21.9% | ||
| Q3 25 | 7.1% | 31.0% | ||
| Q2 25 | 11.3% | 37.7% | ||
| Q1 25 | 0.7% | 43.2% | ||
| Q4 24 | 9.0% | 22.5% | ||
| Q3 24 | 12.4% | 25.1% | ||
| Q2 24 | 8.3% | 33.9% |
资本支出强度ASGNRMD
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 2.0% | ||
| Q3 25 | 1.2% | 3.2% | ||
| Q2 25 | 0.9% | 2.3% | ||
| Q1 25 | 1.1% | 1.6% | ||
| Q4 24 | 1.1% | 1.6% | ||
| Q3 24 | 0.8% | 1.5% | ||
| Q2 24 | 0.5% | 2.0% |
现金转化率ASGNRMD
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 0.87× | ||
| Q3 25 | 2.20× | 1.31× | ||
| Q2 25 | 4.26× | 1.42× | ||
| Q1 25 | 0.80× | 1.59× | ||
| Q4 24 | 2.36× | 0.90× | ||
| Q3 24 | 2.86× | 1.05× | ||
| Q2 24 | 1.92× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASGN
暂无分部数据
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
